Europe Biosimilars Market Forecast to 2030 - Regional Analysis By Disease Indication (Cancer, Diabetes, Autoimmune Disease, and Other Disease Indication), Route of Administration (Intravenous, Subcutaneous, and Others), Drug Class (Granulocyte Colony-Stimulating Factor, Insulin, TNF Blockers and Monoclonal Antibodies, and Others), Distribution Channel (Hospital Pharmacies, Compounding Pharmacies, Retail Pharmacies, and Online Pharmacies), and Region
The Europe biosimilars market is expected to grow from US$ 10,344.86 million in 2022 to US$ 1,15,125.91 million by 2030; it is estimated to grow at a CAGR of 35.1% from 2022 to 2030.
The report highlights trends prevailing in the market and factors driving the market growth. The market growth is attributed to the increasing prevalence of chronic diseases and rising approvals of biosimilars. Additionally, collaborations for biosimilars and clinical trials is likely to emerge as a significant trend in the market during the forecast period. However, high cost involvement and complexities in biosimilar product manufacturing hinders market growth during the forecast period 2022-2030.
Collaborations for Biosimilars and Clinical Trials Drives the Europe Biosimilars Market
Joint ventures and other collaboration models will help biosimilar medicine manufacturers maintain a competitive edge over rivals in the market in the coming years.
By collaborating with other companies planning to research, launch, and market biosimilar drugs, biosimilar manufacturers can develop their products rapidly and launch products effectively in a way that overcomes patent risks and gains clinician and patient confidence in the product. Product development can be expedited by gaining local and foreign expertise, development platform access, and research and clinical trial funding.
Collaborating with a bigger biopharmaceutical manufacturer allows access to established manufacturing facilities. The collaboration can be done for outsourcing activities such as cell line development, biologics and biosimilar manufacturing, process scaling, and any required technology transfer.
There are long-term benefits from collaborations. They can make it easy to tender for future biosimilar production projects within the country and offer early and efficient product development and market penetration. In a sizeable market such as Europe, which has significant country-level diversity in healthcare policies and market dynamics, access to local knowledge obtained through such collaborations can also prove invaluable.
The immense potential of the biosimilars market has led to many recent, high-profile collaborations. A few instances are given below:
In June 2023, Samsung Biologics announced a strategic partnership with Pfizer for the long-term commercial manufacturing of Pfizer's multi-product portfolio. The agreement aims that Samsung Biologics will offer Pfizer additional capacity for large-scale manufacturing of a multi-product biosimilar portfolio encompassing oncology, inflammation, and immunology.
In May 2023, Sandoz, a Novartis division, announced a biosimilar collaboration with Evotec Biologics. The agreement covers developing and manufacturing multiple biosimilar medicines intended for rapid development and the subsequent manufacturing of multiple biosimilars. The development of biosimilars at the Evotec Biologics facility will ramp up under the collaboration in the next 12–18 months.
Thus, collaborations of manufacturers for biosimilar production and clinical trials will be the key trend in the biosimilar market during the forecast period.
Patent Expiry of Blockbuster Biologics Offers Lucrative Market Opportunity
Biologicals represent promising new therapies for previously incurable diseases and are becoming highly important in the pharmaceuticals market. However, patents for originator biologicals are expected to expire in the coming years.
Estimated patent and exclusivity expiry dates for best-selling biologicals are given in the following table .
Biologicals Expiry Month & Years
Avastin January 2022
Cyramza May 2023
Adcetris August 2023
Abthrax October 2024
Gazyva/Gazyvaro November 2024
Darzalex May 2026
Ocrevus April 2027
Emgality September 2028
Hemlibra February 2028
Llumetri March 2028
Imfinzi September 2028
Mylotarg April 2028
Imfinzi September 2028
Mylotarg April 2028
Sylvant July 2034
Source: Generics and Biosimilars Initiative (GaBI) Journal
The patent expiration and other intellectual property rights for originator biologicals will create a need to introduce new biosimilars in the future. As a result, competition among market players will surge in the industry in the coming years. Thus, the patent expiry of blockbuster biologics is expected to create lucrative opportunities for the biosimilar market during the forecast period.
Germany holds largest market share for the Europe biosimilars market from 2022-2030. Biosimilars introduce competition and increase the affordability of biologics, which ultimately deliver savings and value-added services to support patient care and the healthcare community. Healthcare professionals can treat more patients with high-quality biologics while reducing spending. For example, in Germany, according to Sandoz, the number of daily therapeutic doses of an anti-TNF medicine increased by 29% (from 17.18 to 22.18 million) after introducing biosimilars in 2022.
Germany has achieved acceptance of biosimilars with payers, providers, and patients as an integral part of appropriate medicine use. There is full reimbursement from a price set by the company, including immediate patient access to biosimilars. The structure of hospital tendering by multiple buying groups and separate hospital chains allows for competition among manufacturers to be maintained in Germany. For instance, in November 2018, the German Health Ministry introduced a draft bill on safety in the supply of pharmaceuticals. The Gesetz fьr Mehr Sicherheit in der Arzneimittelversor-gung (GSAV) bill aims to provide a legal framework for the automatic substitution of biosimilars by pharmacists in Germany.
Due to the huge potential for cost savings, the German Health Ministry introduced a new law to increase the adoption of biosimilars. As few European Union (EU) countries allow pharmacist substitution of biosimilars, this would represent a significant change in practice, particularly for Germany. Additionally, in Germany, a law passed in 2019 foresees the automatic substitution of biosimilars in pharmacies beginning in 2022, provided the Federal Joint Committee (the highest decision-making body of the self-governance of health insurers and providers) has determined the interchangeability of the medicines in question, and the prescribing physician has not explicitly excluded it. Therefore, with the growing government initiatives for adopting biosimilars in Germany, the market is expected to grow.
Various organic and inorganic strategies are adopted by companies in the Europe biosimilars market. The organic strategies mainly include product launches and product approvals. Further, inorganic growth strategies witnessed in the market are acquisitions, collaborations, and partnerships. These growth strategies allow the market players to expand their businesses and enhance their geographic presence, thereby contributing to the overall market growth. Further, acquisition and partnership strategies help the market players strengthen their customer base and expand their product portfolios. A few of the significant developments by key players in the Europe biosimilars market are listed below.
International Diabetes Federation, European Medicine Agency, Centers for Disease Control and Prevention, Chinese Clinical Oncology, National Comprehensive Care Network are a few of the major primary and secondary sources referred to while preparing the report on the Europe biosimilars market.
The report highlights trends prevailing in the market and factors driving the market growth. The market growth is attributed to the increasing prevalence of chronic diseases and rising approvals of biosimilars. Additionally, collaborations for biosimilars and clinical trials is likely to emerge as a significant trend in the market during the forecast period. However, high cost involvement and complexities in biosimilar product manufacturing hinders market growth during the forecast period 2022-2030.
Collaborations for Biosimilars and Clinical Trials Drives the Europe Biosimilars Market
Joint ventures and other collaboration models will help biosimilar medicine manufacturers maintain a competitive edge over rivals in the market in the coming years.
By collaborating with other companies planning to research, launch, and market biosimilar drugs, biosimilar manufacturers can develop their products rapidly and launch products effectively in a way that overcomes patent risks and gains clinician and patient confidence in the product. Product development can be expedited by gaining local and foreign expertise, development platform access, and research and clinical trial funding.
Collaborating with a bigger biopharmaceutical manufacturer allows access to established manufacturing facilities. The collaboration can be done for outsourcing activities such as cell line development, biologics and biosimilar manufacturing, process scaling, and any required technology transfer.
There are long-term benefits from collaborations. They can make it easy to tender for future biosimilar production projects within the country and offer early and efficient product development and market penetration. In a sizeable market such as Europe, which has significant country-level diversity in healthcare policies and market dynamics, access to local knowledge obtained through such collaborations can also prove invaluable.
The immense potential of the biosimilars market has led to many recent, high-profile collaborations. A few instances are given below:
In June 2023, Samsung Biologics announced a strategic partnership with Pfizer for the long-term commercial manufacturing of Pfizer's multi-product portfolio. The agreement aims that Samsung Biologics will offer Pfizer additional capacity for large-scale manufacturing of a multi-product biosimilar portfolio encompassing oncology, inflammation, and immunology.
In May 2023, Sandoz, a Novartis division, announced a biosimilar collaboration with Evotec Biologics. The agreement covers developing and manufacturing multiple biosimilar medicines intended for rapid development and the subsequent manufacturing of multiple biosimilars. The development of biosimilars at the Evotec Biologics facility will ramp up under the collaboration in the next 12–18 months.
Thus, collaborations of manufacturers for biosimilar production and clinical trials will be the key trend in the biosimilar market during the forecast period.
Patent Expiry of Blockbuster Biologics Offers Lucrative Market Opportunity
Biologicals represent promising new therapies for previously incurable diseases and are becoming highly important in the pharmaceuticals market. However, patents for originator biologicals are expected to expire in the coming years.
Estimated patent and exclusivity expiry dates for best-selling biologicals are given in the following table .
Biologicals Expiry Month & Years
Avastin January 2022
Cyramza May 2023
Adcetris August 2023
Abthrax October 2024
Gazyva/Gazyvaro November 2024
Darzalex May 2026
Ocrevus April 2027
Emgality September 2028
Hemlibra February 2028
Llumetri March 2028
Imfinzi September 2028
Mylotarg April 2028
Imfinzi September 2028
Mylotarg April 2028
Sylvant July 2034
Source: Generics and Biosimilars Initiative (GaBI) Journal
The patent expiration and other intellectual property rights for originator biologicals will create a need to introduce new biosimilars in the future. As a result, competition among market players will surge in the industry in the coming years. Thus, the patent expiry of blockbuster biologics is expected to create lucrative opportunities for the biosimilar market during the forecast period.
Germany holds largest market share for the Europe biosimilars market from 2022-2030. Biosimilars introduce competition and increase the affordability of biologics, which ultimately deliver savings and value-added services to support patient care and the healthcare community. Healthcare professionals can treat more patients with high-quality biologics while reducing spending. For example, in Germany, according to Sandoz, the number of daily therapeutic doses of an anti-TNF medicine increased by 29% (from 17.18 to 22.18 million) after introducing biosimilars in 2022.
Germany has achieved acceptance of biosimilars with payers, providers, and patients as an integral part of appropriate medicine use. There is full reimbursement from a price set by the company, including immediate patient access to biosimilars. The structure of hospital tendering by multiple buying groups and separate hospital chains allows for competition among manufacturers to be maintained in Germany. For instance, in November 2018, the German Health Ministry introduced a draft bill on safety in the supply of pharmaceuticals. The Gesetz fьr Mehr Sicherheit in der Arzneimittelversor-gung (GSAV) bill aims to provide a legal framework for the automatic substitution of biosimilars by pharmacists in Germany.
Due to the huge potential for cost savings, the German Health Ministry introduced a new law to increase the adoption of biosimilars. As few European Union (EU) countries allow pharmacist substitution of biosimilars, this would represent a significant change in practice, particularly for Germany. Additionally, in Germany, a law passed in 2019 foresees the automatic substitution of biosimilars in pharmacies beginning in 2022, provided the Federal Joint Committee (the highest decision-making body of the self-governance of health insurers and providers) has determined the interchangeability of the medicines in question, and the prescribing physician has not explicitly excluded it. Therefore, with the growing government initiatives for adopting biosimilars in Germany, the market is expected to grow.
Various organic and inorganic strategies are adopted by companies in the Europe biosimilars market. The organic strategies mainly include product launches and product approvals. Further, inorganic growth strategies witnessed in the market are acquisitions, collaborations, and partnerships. These growth strategies allow the market players to expand their businesses and enhance their geographic presence, thereby contributing to the overall market growth. Further, acquisition and partnership strategies help the market players strengthen their customer base and expand their product portfolios. A few of the significant developments by key players in the Europe biosimilars market are listed below.
International Diabetes Federation, European Medicine Agency, Centers for Disease Control and Prevention, Chinese Clinical Oncology, National Comprehensive Care Network are a few of the major primary and secondary sources referred to while preparing the report on the Europe biosimilars market.
1. INTRODUCTION
1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation
2. EUROPE BIOSIMILARS MARKET – KEY TAKEAWAYS
3. RESEARCH METHODOLOGY
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. EUROPE BIOSIMILARS MARKET – MARKET LANDSCAPE
4.1 Overview
4.1.1 Europe PEST Analysis
4.2 Actual Market Price/Net Price
4.2.1 France
4.2.2 Germany
4.2.3 Italy
4.2.4 Spain
4.2.5 UK
5. EUROPE BIOSIMILARS MARKET
5.1 Market Drivers
5.1.1 Increasing Prevalence of Chronic Diseases
5.1.2 Rising Approvals of Biosimilars
5.2 Market Restraints
5.2.1 High Cost Involvement and Complexities in Biosimilar Product Manufacturing
5.3 Market Opportunities
5.3.1 Patent Expiry of Blockbuster Biologics
5.4 Future Trends
5.4.1 Collaborations for Biosimilars and Clinical Trials
5.5 Impact analysis
6. EUROPE BIOSIMILARS MARKET – REGIONAL ANALYSIS
6.1 Europe Biosimilars Market Revenue Forecast and Analysis
7. EUROPE BIOSIMILARS MARKET – REVENUE AND FORECAST TO 2030 – BY DISEASE INDICATION
7.1 Overview
7.2 Europe Biosimilars Market Revenue Share, by Type 2022 & 2030 (%)
7.3 Cancer
7.3.1 Overview
7.3.2 Cancer: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
7.4 Diabetes
7.4.1 Overview
7.4.2 Diabetes: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
7.5 Autoimmune Diseases
7.5.1 Overview
7.5.2 Autoimmune Diseases: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
7.5.3 Psoriasis
7.5.3.1 Overview
7.5.4 Psoriasis: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
7.5.5 Arthritis
7.5.5.1 Overview
7.5.6 Arthritis: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
7.5.7 Others
7.5.7.1 Overview
7.5.7.2 Others: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
7.6 Other Disease Indication
7.6.1 Overview
7.6.2 Other Disease Indication: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
8. EUROPE BIOSIMILARS MARKET ANALYSIS AND FORECASTS TO 2028 – BY ROUTE OF ADMINISTRATION
8.1 Overview
8.2 Europe Biosimilars Market, by Route of Administration 2022 & 2030 (%)
8.3 Intravenous
8.3.1 Overview
8.3.2 Intravenous: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
8.4 Subcutaneous
8.4.1 Overview
8.4.2 Subcutaneous: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
8.5 Others
8.5.1 Overview
8.5.2 Others: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
9. EUROPE BIOSIMILARS MARKET – REVENUE AND FORECAST TO 2030 – BY DRUG CLASS
9.1 Overview
9.2 Europe Biosimilars Market Revenue Share, by Drug Class 2022 & 2030 (%)
9.3 Granulocyte Colony-Stimulating Factor
9.3.1 Overview
9.3.2 Granulocyte Colony-Stimulating Factor: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
9.4 Insulin
9.4.1 Overview
9.4.2 Insulin: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
9.5 TNF Blockers and Monoclonal Antibodies
9.5.1 Overview
9.5.2 TNF Blockers and Monoclonal Antibodies: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
9.6 Others
9.6.1 Overview
9.6.2 Others: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
10. EUROPE BIOSIMILARS MARKET – REVENUE AND FORECAST TO 2030 – BY DISTRIBUTION CHANNEL
10.1 Overview
10.2 Europe Biosimilars Market Revenue Share, by Distribution Channel 2022 & 2030 (%)
10.3 Endocrinologists
10.3.1 Overview
10.4 Immunologists
10.4.1 Overview
10.5 Rheumatologists
10.5.1 Overview
10.6 Oncologists
10.6.1 Overview
10.7 Dermatologists
10.7.1 Overview
10.8 Retina Compounding
10.8.1 Overview
10.9 Others
10.9.1 Overview
10.10 Hospital Pharmacies
10.10.1 Overview
10.10.2 Hospital Pharmacies: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
10.10.3 Endocrinologists
10.10.3.1 Endocrinologists: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
10.10.4 Immunologists
10.10.4.1 Immunologists: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
10.10.5 Rheumatologists
10.10.5.1 Rheumatologists: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
10.10.6 Oncologists
10.10.6.1 Oncologists: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
10.10.7 Dermatologists
10.10.7.1 Dermatologists: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
10.10.8 Retina Specialists
10.10.8.1 Retina Specialists: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
10.10.9 Others
10.10.9.1 Others: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
10.11 Compounding Pharmacies
10.11.1 Overview
10.11.2 Compounding Pharmacies : Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
10.11.3 Endocrinologists
10.11.3.1 Endocrinologists: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
10.11.4 Immunologists
10.11.4.1 Immunologists: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
10.11.5 Rheumatologists
10.11.5.1 Rheumatologists: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
10.11.6 Oncologists
10.11.6.1 Oncologists: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
10.11.7 Dermatologists
10.11.7.1 Dermatologists: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
10.11.8 Retina Specialists
10.11.8.1 Retina Specialists: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
10.11.9 Others
10.11.9.1 Others: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
10.12 Retail Pharmacies
10.12.1 Overview
10.12.2 Retail Pharmacies: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
10.12.3 Endocrinologists
10.12.3.1 Endocrinologists: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
10.12.4 Immunologists
10.12.4.1 Immunologists: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
10.12.5 Rheumatologists
10.12.5.1 Rheumatologists: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
10.12.6 Oncologists
10.12.6.1 Oncologists: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
10.12.7 Dermatologists
10.12.7.1 Dermatologists: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
10.12.8 Retina Specialists
10.12.8.1 Retina Specialists: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
10.12.9 Others
10.12.9.1 Others: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
10.13 Online Pharmacies
10.13.1 Overview
10.13.2 Online Pharmacies: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
10.13.3 Endocrinologists
10.13.3.1 Endocrinologists: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
10.13.4 Immunologists
10.13.4.1 Immunologists: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
10.13.5 Rheumatologists
10.13.5.1 Rheumatologists: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
10.13.6 Oncologists
10.13.6.1 Oncologists: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
10.13.7 Dermatologists
10.13.7.1 Dermatologists: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
10.13.8 Retina Specialists
10.13.8.1 Retina Specialists: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
10.13.9 Others
10.13.9.1 Others: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
11. EUROPE BIOSIMILARS MARKET – REVENUE AND FORECAST TO 2030 – GEOGRAPHIC ANALYSIS
11.1 Europe Biosimilars Market, Revenue and Forecast to 2030
11.1.1 Overview
11.1.2 Europe Biosimilars Market Revenue and Forecast to 2030 (US$ Mn)
11.1.2.1 Europe Biosimilars Market, by Disease Indication
11.1.2.2 Europe Biosimilars Market, by Autoimmune Diseases
11.1.2.3 Europe Biosimilars Market, by Route of Administration
11.1.2.4 Europe Biosimilars Market, by Drug Class
11.1.2.5 Europe Biosimilars Market, by Distribution Channel
11.1.2.6 Europe Biosimilars Market, by Hospital Pharmacies
11.1.2.7 Europe Biosimilars Market, by Compounding Pharmacies
11.1.2.8 Europe Biosimilars Market, by Retail Pharmacies
11.1.2.9 Europe Biosimilars Market, by Online Pharmacies
11.1.2.10 Europe Biosimilars Market by Country
11.1.2.10.1 Germany
11.1.2.10.1.1 Overview
11.1.2.10.1.2 Germany Biosimilars Market Revenue and Forecast to 2030 (US$ Mn)
11.1.2.10.1.2.1 Germany Biosimilars Market, by Disease Indication
11.1.2.10.1.2.2 Germany Biosimilars Market, by Autoimmune Diseases
11.1.2.10.1.2.3 Germany Biosimilars Market, by Route of Administration
11.1.2.10.1.2.4 Germany Biosimilars Market, by Drug Class
11.1.2.10.1.2.5 Germany Biosimilars Market, by Distribution Channel
11.1.2.10.1.2.6 Germany Biosimilars Market, by Hospital Pharmacies
11.1.2.10.1.2.7 Germany Biosimilars Market, by Compounding Pharmacies
11.1.2.10.1.2.8 Germany Biosimilars Market, by Retail Pharmacies
11.1.2.10.1.2.9 Germany Biosimilars Market, by Online Pharmacies
11.1.2.10.2 UK
11.1.2.10.3 Overview
11.1.2.10.3.1 UK Biosimilars Market Revenue and Forecast to 2030 (US$ Mn)
11.1.2.10.3.1.1 UK Biosimilars Market, by Disease Indication
11.1.2.10.3.1.2 UK Biosimilars Market, by Autoimmune Diseases
11.1.2.10.3.1.3 UK Biosimilars Market, by Route of Administration
11.1.2.10.3.1.4 UK Biosimilars Market, by Drug Class
11.1.2.10.3.1.5 UK Biosimilars Market, by Distribution Channel
11.1.2.10.3.1.6 UK Biosimilars Market, by Hospital Pharmacies
11.1.2.10.3.1.7 UK Biosimilars Market, by Compounding Pharmacies
11.1.2.10.3.1.8 UK Biosimilars Market, by Retail Pharmacies
11.1.2.10.3.1.9 UK Biosimilars Market, by Online Pharmacies
11.1.2.10.4 France
11.1.2.10.4.1 Overview
11.1.2.10.4.2 France Biosimilars Market Revenue and Forecast to 2030 (US$ Mn)
11.1.2.10.4.2.1 France Biosimilars Market, by Disease Indication
11.1.2.10.4.2.2 France Biosimilars Market, by Autoimmune Diseases
11.1.2.10.4.2.3 France Biosimilars Market, by Route of Administration
11.1.2.10.4.2.4 France Biosimilars Market, by Drug Class
11.1.2.10.4.2.5 France Biosimilars Market, by Distribution Channel
11.1.2.10.4.2.6 France Biosimilars Market, by Hospital Pharmacies
11.1.2.10.4.2.7 France Biosimilars Market, by Compounding Pharmacies
11.1.2.10.4.2.8 France Biosimilars Market, by Retail Pharmacies
11.1.2.10.4.2.9 France Biosimilars Market, by Online Pharmacies
11.1.2.10.5 Italy
11.1.2.10.5.1 Overview
11.1.2.10.5.2 Italy Biosimilars Market Revenue and Forecast to 2030 (US$ Mn)
11.1.2.10.5.2.1 Italy Biosimilars Market, by Disease Indication
11.1.2.10.5.2.2 Italy Biosimilars Market, by Autoimmune Diseases
11.1.2.10.5.2.3 Italy Biosimilars Market, by Route of Administration
11.1.2.10.5.2.4 Italy Biosimilars Market, by Drug Class
11.1.2.10.5.2.5 Italy Biosimilars Market, by Distribution Channel
11.1.2.10.5.2.6 Italy Biosimilars Market, by Hospital Pharmacies
11.1.2.10.5.2.7 Italy Biosimilars Market, by Compounding Pharmacies
11.1.2.10.5.2.8 Italy Biosimilars Market, by Retail Pharmacies
11.1.2.10.5.2.9 Italy Biosimilars Market, by Online Pharmacies
11.1.2.10.6 Spain
11.1.2.10.6.1 Overview
11.1.2.10.6.2 Spain Biosimilars Market Revenue and Forecast to 2030 (US$ Mn)
11.1.2.10.6.2.1 Spain Biosimilars Market, by Disease Indication
11.1.2.10.6.2.2 Spain Biosimilars Market, by Autoimmune Diseases
11.1.2.10.6.2.3 Spain Biosimilars Market, by Route of Administration
11.1.2.10.6.2.4 Spain Biosimilars Market, by Drug Class
11.1.2.10.6.2.5 Spain Biosimilars Market, by Distribution Channel
11.1.2.10.6.2.6 Spain Biosimilars Market, by Hospital Pharmacies
11.1.2.10.6.2.7 Spain Biosimilars Market, by Compounding Pharmacies
11.1.2.10.6.2.8 Spain Biosimilars Market, by Retail Pharmacies
11.1.2.10.6.2.9 Spain Biosimilars Market, by Online Pharmacies
11.1.2.10.7 Rest of Europe
11.1.2.10.7.1 Overview
11.1.2.10.7.2 Rest of Europe Biosimilars Market Revenue and Forecast to 2030 (US$ Mn)
11.1.2.10.7.2.1 Rest of Europe Biosimilars Market, by Disease Indication
11.1.2.10.7.2.2 Rest of Europe Biosimilars Market, by Autoimmune Diseases
11.1.2.10.7.2.3 Rest of Europe Biosimilars Market, by Route of Administration
11.1.2.10.7.2.4 Rest of Europe Biosimilars Market, by Drug Class
11.1.2.10.7.2.5 Rest of Europe Biosimilars Market, by Distribution Channel
11.1.2.10.7.2.6 Rest of Europe Biosimilars Market, by Hospital Pharmacies
11.1.2.10.7.2.7 Rest of Europe Biosimilars Market, by Compounding Pharmacies
11.1.2.10.7.2.8 Rest of Europe Biosimilars Market, by Retail Pharmacies
11.1.2.10.7.2.9 Rest of Europe Biosimilars Market, by Online Pharmacies
12. PRE AND POST COVID-19 IMPACT
12.1 Pre and Post COVID-19 Impact
13. BIOSIMILARS MARKET – INDUSTRY LANDSCAPE
13.1 Overview
13.2 Growth Strategies in Biosimilars Market
13.3 Inorganic Growth Strategies
13.3.1 Overview
13.4 Organic Growth Strategies
13.4.1 Overview
14. COMPANY PROFILES
14.1 Amgen Inc
14.1.1 Key Facts
14.1.2 Business Description
14.1.3 Products and Services
14.1.4 Financial Overview
14.1.5 SWOT Analysis
14.1.6 Key Developments
14.2 Celltrion Inc
14.2.1 Key Facts
14.2.2 Business Description
14.2.3 Products and Services
14.2.4 Financial Overview
14.2.5 SWOT Analysis
14.2.6 Key Developments
14.3 Sanofi SA
14.3.1 Key Facts
14.3.2 Business Description
14.3.3 Products and Services
14.3.4 Financial Overview
14.3.5 SWOT Analysis
14.4 Biocon Ltd
14.4.1 Key Facts
14.4.2 Business Description
14.4.3 Products and Services
14.4.4 Financial Overview
14.4.5 SWOT Analysis
14.4.6 Key Developments
14.5 Samsung Bioepis Co Ltd
14.5.1 Key Facts
14.5.2 Business Description
14.5.3 Products and Services
14.5.4 Financial Overview
14.5.5 SWOT Analysis
14.5.6 Key Developments
14.6 Eli Lilly and Co
14.6.1 Key Facts
14.6.2 Business Description
14.6.3 Products and Services
14.6.4 Financial Overview
14.6.5 SWOT Analysis
14.6.6 Key Developments
14.7 Sandoz AG
14.7.1 Key Facts
14.7.2 Business Description
14.7.3 Products and Services
14.7.4 Financial Overview
14.7.5 SWOT Analysis
14.7.6 Key Developments
14.8 Teva Pharmaceutical Industries Ltd
14.8.1 Key Facts
14.8.2 Business Description
14.8.3 Products and Services
14.8.4 Financial Overview
14.8.5 SWOT Analysis
14.8.6 Key Developments
14.9 Pfizer Inc
14.9.1 Key Facts
14.9.2 Business Description
14.9.3 Products and Services
14.9.4 Financial Overview
14.9.5 SWOT Analysis
14.9.6 Key Developments
14.10 Dr. Reddy's Laboratories Ltd
14.10.1 Key Facts
14.10.2 Business Description
14.10.3 Products and Services
14.10.4 Financial Overview
14.10.5 SWOT Analysis
14.10.6 Key Developments
15. APPENDIX
15.1 About The Insight Partners
15.2 Glossary of Terms
1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation
2. EUROPE BIOSIMILARS MARKET – KEY TAKEAWAYS
3. RESEARCH METHODOLOGY
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. EUROPE BIOSIMILARS MARKET – MARKET LANDSCAPE
4.1 Overview
4.1.1 Europe PEST Analysis
4.2 Actual Market Price/Net Price
4.2.1 France
4.2.2 Germany
4.2.3 Italy
4.2.4 Spain
4.2.5 UK
5. EUROPE BIOSIMILARS MARKET
5.1 Market Drivers
5.1.1 Increasing Prevalence of Chronic Diseases
5.1.2 Rising Approvals of Biosimilars
5.2 Market Restraints
5.2.1 High Cost Involvement and Complexities in Biosimilar Product Manufacturing
5.3 Market Opportunities
5.3.1 Patent Expiry of Blockbuster Biologics
5.4 Future Trends
5.4.1 Collaborations for Biosimilars and Clinical Trials
5.5 Impact analysis
6. EUROPE BIOSIMILARS MARKET – REGIONAL ANALYSIS
6.1 Europe Biosimilars Market Revenue Forecast and Analysis
7. EUROPE BIOSIMILARS MARKET – REVENUE AND FORECAST TO 2030 – BY DISEASE INDICATION
7.1 Overview
7.2 Europe Biosimilars Market Revenue Share, by Type 2022 & 2030 (%)
7.3 Cancer
7.3.1 Overview
7.3.2 Cancer: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
7.4 Diabetes
7.4.1 Overview
7.4.2 Diabetes: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
7.5 Autoimmune Diseases
7.5.1 Overview
7.5.2 Autoimmune Diseases: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
7.5.3 Psoriasis
7.5.3.1 Overview
7.5.4 Psoriasis: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
7.5.5 Arthritis
7.5.5.1 Overview
7.5.6 Arthritis: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
7.5.7 Others
7.5.7.1 Overview
7.5.7.2 Others: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
7.6 Other Disease Indication
7.6.1 Overview
7.6.2 Other Disease Indication: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
8. EUROPE BIOSIMILARS MARKET ANALYSIS AND FORECASTS TO 2028 – BY ROUTE OF ADMINISTRATION
8.1 Overview
8.2 Europe Biosimilars Market, by Route of Administration 2022 & 2030 (%)
8.3 Intravenous
8.3.1 Overview
8.3.2 Intravenous: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
8.4 Subcutaneous
8.4.1 Overview
8.4.2 Subcutaneous: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
8.5 Others
8.5.1 Overview
8.5.2 Others: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
9. EUROPE BIOSIMILARS MARKET – REVENUE AND FORECAST TO 2030 – BY DRUG CLASS
9.1 Overview
9.2 Europe Biosimilars Market Revenue Share, by Drug Class 2022 & 2030 (%)
9.3 Granulocyte Colony-Stimulating Factor
9.3.1 Overview
9.3.2 Granulocyte Colony-Stimulating Factor: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
9.4 Insulin
9.4.1 Overview
9.4.2 Insulin: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
9.5 TNF Blockers and Monoclonal Antibodies
9.5.1 Overview
9.5.2 TNF Blockers and Monoclonal Antibodies: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
9.6 Others
9.6.1 Overview
9.6.2 Others: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
10. EUROPE BIOSIMILARS MARKET – REVENUE AND FORECAST TO 2030 – BY DISTRIBUTION CHANNEL
10.1 Overview
10.2 Europe Biosimilars Market Revenue Share, by Distribution Channel 2022 & 2030 (%)
10.3 Endocrinologists
10.3.1 Overview
10.4 Immunologists
10.4.1 Overview
10.5 Rheumatologists
10.5.1 Overview
10.6 Oncologists
10.6.1 Overview
10.7 Dermatologists
10.7.1 Overview
10.8 Retina Compounding
10.8.1 Overview
10.9 Others
10.9.1 Overview
10.10 Hospital Pharmacies
10.10.1 Overview
10.10.2 Hospital Pharmacies: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
10.10.3 Endocrinologists
10.10.3.1 Endocrinologists: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
10.10.4 Immunologists
10.10.4.1 Immunologists: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
10.10.5 Rheumatologists
10.10.5.1 Rheumatologists: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
10.10.6 Oncologists
10.10.6.1 Oncologists: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
10.10.7 Dermatologists
10.10.7.1 Dermatologists: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
10.10.8 Retina Specialists
10.10.8.1 Retina Specialists: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
10.10.9 Others
10.10.9.1 Others: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
10.11 Compounding Pharmacies
10.11.1 Overview
10.11.2 Compounding Pharmacies : Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
10.11.3 Endocrinologists
10.11.3.1 Endocrinologists: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
10.11.4 Immunologists
10.11.4.1 Immunologists: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
10.11.5 Rheumatologists
10.11.5.1 Rheumatologists: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
10.11.6 Oncologists
10.11.6.1 Oncologists: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
10.11.7 Dermatologists
10.11.7.1 Dermatologists: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
10.11.8 Retina Specialists
10.11.8.1 Retina Specialists: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
10.11.9 Others
10.11.9.1 Others: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
10.12 Retail Pharmacies
10.12.1 Overview
10.12.2 Retail Pharmacies: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
10.12.3 Endocrinologists
10.12.3.1 Endocrinologists: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
10.12.4 Immunologists
10.12.4.1 Immunologists: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
10.12.5 Rheumatologists
10.12.5.1 Rheumatologists: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
10.12.6 Oncologists
10.12.6.1 Oncologists: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
10.12.7 Dermatologists
10.12.7.1 Dermatologists: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
10.12.8 Retina Specialists
10.12.8.1 Retina Specialists: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
10.12.9 Others
10.12.9.1 Others: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
10.13 Online Pharmacies
10.13.1 Overview
10.13.2 Online Pharmacies: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
10.13.3 Endocrinologists
10.13.3.1 Endocrinologists: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
10.13.4 Immunologists
10.13.4.1 Immunologists: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
10.13.5 Rheumatologists
10.13.5.1 Rheumatologists: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
10.13.6 Oncologists
10.13.6.1 Oncologists: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
10.13.7 Dermatologists
10.13.7.1 Dermatologists: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
10.13.8 Retina Specialists
10.13.8.1 Retina Specialists: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
10.13.9 Others
10.13.9.1 Others: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
11. EUROPE BIOSIMILARS MARKET – REVENUE AND FORECAST TO 2030 – GEOGRAPHIC ANALYSIS
11.1 Europe Biosimilars Market, Revenue and Forecast to 2030
11.1.1 Overview
11.1.2 Europe Biosimilars Market Revenue and Forecast to 2030 (US$ Mn)
11.1.2.1 Europe Biosimilars Market, by Disease Indication
11.1.2.2 Europe Biosimilars Market, by Autoimmune Diseases
11.1.2.3 Europe Biosimilars Market, by Route of Administration
11.1.2.4 Europe Biosimilars Market, by Drug Class
11.1.2.5 Europe Biosimilars Market, by Distribution Channel
11.1.2.6 Europe Biosimilars Market, by Hospital Pharmacies
11.1.2.7 Europe Biosimilars Market, by Compounding Pharmacies
11.1.2.8 Europe Biosimilars Market, by Retail Pharmacies
11.1.2.9 Europe Biosimilars Market, by Online Pharmacies
11.1.2.10 Europe Biosimilars Market by Country
11.1.2.10.1 Germany
11.1.2.10.1.1 Overview
11.1.2.10.1.2 Germany Biosimilars Market Revenue and Forecast to 2030 (US$ Mn)
11.1.2.10.1.2.1 Germany Biosimilars Market, by Disease Indication
11.1.2.10.1.2.2 Germany Biosimilars Market, by Autoimmune Diseases
11.1.2.10.1.2.3 Germany Biosimilars Market, by Route of Administration
11.1.2.10.1.2.4 Germany Biosimilars Market, by Drug Class
11.1.2.10.1.2.5 Germany Biosimilars Market, by Distribution Channel
11.1.2.10.1.2.6 Germany Biosimilars Market, by Hospital Pharmacies
11.1.2.10.1.2.7 Germany Biosimilars Market, by Compounding Pharmacies
11.1.2.10.1.2.8 Germany Biosimilars Market, by Retail Pharmacies
11.1.2.10.1.2.9 Germany Biosimilars Market, by Online Pharmacies
11.1.2.10.2 UK
11.1.2.10.3 Overview
11.1.2.10.3.1 UK Biosimilars Market Revenue and Forecast to 2030 (US$ Mn)
11.1.2.10.3.1.1 UK Biosimilars Market, by Disease Indication
11.1.2.10.3.1.2 UK Biosimilars Market, by Autoimmune Diseases
11.1.2.10.3.1.3 UK Biosimilars Market, by Route of Administration
11.1.2.10.3.1.4 UK Biosimilars Market, by Drug Class
11.1.2.10.3.1.5 UK Biosimilars Market, by Distribution Channel
11.1.2.10.3.1.6 UK Biosimilars Market, by Hospital Pharmacies
11.1.2.10.3.1.7 UK Biosimilars Market, by Compounding Pharmacies
11.1.2.10.3.1.8 UK Biosimilars Market, by Retail Pharmacies
11.1.2.10.3.1.9 UK Biosimilars Market, by Online Pharmacies
11.1.2.10.4 France
11.1.2.10.4.1 Overview
11.1.2.10.4.2 France Biosimilars Market Revenue and Forecast to 2030 (US$ Mn)
11.1.2.10.4.2.1 France Biosimilars Market, by Disease Indication
11.1.2.10.4.2.2 France Biosimilars Market, by Autoimmune Diseases
11.1.2.10.4.2.3 France Biosimilars Market, by Route of Administration
11.1.2.10.4.2.4 France Biosimilars Market, by Drug Class
11.1.2.10.4.2.5 France Biosimilars Market, by Distribution Channel
11.1.2.10.4.2.6 France Biosimilars Market, by Hospital Pharmacies
11.1.2.10.4.2.7 France Biosimilars Market, by Compounding Pharmacies
11.1.2.10.4.2.8 France Biosimilars Market, by Retail Pharmacies
11.1.2.10.4.2.9 France Biosimilars Market, by Online Pharmacies
11.1.2.10.5 Italy
11.1.2.10.5.1 Overview
11.1.2.10.5.2 Italy Biosimilars Market Revenue and Forecast to 2030 (US$ Mn)
11.1.2.10.5.2.1 Italy Biosimilars Market, by Disease Indication
11.1.2.10.5.2.2 Italy Biosimilars Market, by Autoimmune Diseases
11.1.2.10.5.2.3 Italy Biosimilars Market, by Route of Administration
11.1.2.10.5.2.4 Italy Biosimilars Market, by Drug Class
11.1.2.10.5.2.5 Italy Biosimilars Market, by Distribution Channel
11.1.2.10.5.2.6 Italy Biosimilars Market, by Hospital Pharmacies
11.1.2.10.5.2.7 Italy Biosimilars Market, by Compounding Pharmacies
11.1.2.10.5.2.8 Italy Biosimilars Market, by Retail Pharmacies
11.1.2.10.5.2.9 Italy Biosimilars Market, by Online Pharmacies
11.1.2.10.6 Spain
11.1.2.10.6.1 Overview
11.1.2.10.6.2 Spain Biosimilars Market Revenue and Forecast to 2030 (US$ Mn)
11.1.2.10.6.2.1 Spain Biosimilars Market, by Disease Indication
11.1.2.10.6.2.2 Spain Biosimilars Market, by Autoimmune Diseases
11.1.2.10.6.2.3 Spain Biosimilars Market, by Route of Administration
11.1.2.10.6.2.4 Spain Biosimilars Market, by Drug Class
11.1.2.10.6.2.5 Spain Biosimilars Market, by Distribution Channel
11.1.2.10.6.2.6 Spain Biosimilars Market, by Hospital Pharmacies
11.1.2.10.6.2.7 Spain Biosimilars Market, by Compounding Pharmacies
11.1.2.10.6.2.8 Spain Biosimilars Market, by Retail Pharmacies
11.1.2.10.6.2.9 Spain Biosimilars Market, by Online Pharmacies
11.1.2.10.7 Rest of Europe
11.1.2.10.7.1 Overview
11.1.2.10.7.2 Rest of Europe Biosimilars Market Revenue and Forecast to 2030 (US$ Mn)
11.1.2.10.7.2.1 Rest of Europe Biosimilars Market, by Disease Indication
11.1.2.10.7.2.2 Rest of Europe Biosimilars Market, by Autoimmune Diseases
11.1.2.10.7.2.3 Rest of Europe Biosimilars Market, by Route of Administration
11.1.2.10.7.2.4 Rest of Europe Biosimilars Market, by Drug Class
11.1.2.10.7.2.5 Rest of Europe Biosimilars Market, by Distribution Channel
11.1.2.10.7.2.6 Rest of Europe Biosimilars Market, by Hospital Pharmacies
11.1.2.10.7.2.7 Rest of Europe Biosimilars Market, by Compounding Pharmacies
11.1.2.10.7.2.8 Rest of Europe Biosimilars Market, by Retail Pharmacies
11.1.2.10.7.2.9 Rest of Europe Biosimilars Market, by Online Pharmacies
12. PRE AND POST COVID-19 IMPACT
12.1 Pre and Post COVID-19 Impact
13. BIOSIMILARS MARKET – INDUSTRY LANDSCAPE
13.1 Overview
13.2 Growth Strategies in Biosimilars Market
13.3 Inorganic Growth Strategies
13.3.1 Overview
13.4 Organic Growth Strategies
13.4.1 Overview
14. COMPANY PROFILES
14.1 Amgen Inc
14.1.1 Key Facts
14.1.2 Business Description
14.1.3 Products and Services
14.1.4 Financial Overview
14.1.5 SWOT Analysis
14.1.6 Key Developments
14.2 Celltrion Inc
14.2.1 Key Facts
14.2.2 Business Description
14.2.3 Products and Services
14.2.4 Financial Overview
14.2.5 SWOT Analysis
14.2.6 Key Developments
14.3 Sanofi SA
14.3.1 Key Facts
14.3.2 Business Description
14.3.3 Products and Services
14.3.4 Financial Overview
14.3.5 SWOT Analysis
14.4 Biocon Ltd
14.4.1 Key Facts
14.4.2 Business Description
14.4.3 Products and Services
14.4.4 Financial Overview
14.4.5 SWOT Analysis
14.4.6 Key Developments
14.5 Samsung Bioepis Co Ltd
14.5.1 Key Facts
14.5.2 Business Description
14.5.3 Products and Services
14.5.4 Financial Overview
14.5.5 SWOT Analysis
14.5.6 Key Developments
14.6 Eli Lilly and Co
14.6.1 Key Facts
14.6.2 Business Description
14.6.3 Products and Services
14.6.4 Financial Overview
14.6.5 SWOT Analysis
14.6.6 Key Developments
14.7 Sandoz AG
14.7.1 Key Facts
14.7.2 Business Description
14.7.3 Products and Services
14.7.4 Financial Overview
14.7.5 SWOT Analysis
14.7.6 Key Developments
14.8 Teva Pharmaceutical Industries Ltd
14.8.1 Key Facts
14.8.2 Business Description
14.8.3 Products and Services
14.8.4 Financial Overview
14.8.5 SWOT Analysis
14.8.6 Key Developments
14.9 Pfizer Inc
14.9.1 Key Facts
14.9.2 Business Description
14.9.3 Products and Services
14.9.4 Financial Overview
14.9.5 SWOT Analysis
14.9.6 Key Developments
14.10 Dr. Reddy's Laboratories Ltd
14.10.1 Key Facts
14.10.2 Business Description
14.10.3 Products and Services
14.10.4 Financial Overview
14.10.5 SWOT Analysis
14.10.6 Key Developments
15. APPENDIX
15.1 About The Insight Partners
15.2 Glossary of Terms
LIST OF TABLES
Table 1. Comparison Between Different Drug Developments
Table 2. Europe Biosimilars Market Revenue And Forecast to 2030 (US$ Mn) – Disease Indication
Table 3. Europe Biosimilars Market Revenue And Forecast to 2030 (US$ Mn) – Autoimmune Diseases
Table 4. Europe Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) – Route of Administration
Table 5. Europe Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) – Drug Class
Table 6. Europe Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) – Distribution Channel
Table 7. Europe Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) – Hospital Pharmacies
Table 8. Europe Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) – Compounding Pharmacies
Table 9. Europe Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) – Retail Pharmacies
Table 10. Europe Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) – Online Pharmacies
Table 11. Germany Biosimilars Market Revenue And Forecast to 2030 (US$ Mn) – Disease Indication
Table 12. Germany Biosimilars Market Revenue And Forecast to 2030 (US$ Mn) – Autoimmune Diseases
Table 13. Germany Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) – Route of Administration
Table 14. Germany Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) – Drug Class
Table 15. Germany Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) – Distribution Channel
Table 16. Germany Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) – Hospital Pharmacies
Table 17. Germany Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) – Compounding Pharmacies
Table 18. Germany Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) – Retail Pharmacies
Table 19. Germany Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) – Online Pharmacies
Table 20. UK Biosimilars Market Revenue And Forecast to 2030 (US$ Mn) – Disease Indication
Table 21. UK Biosimilars Market Revenue And Forecast to 2030 (US$ Mn) – Autoimmune Diseases
Table 22. UK Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) – Route of Administration
Table 23. UK Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) – Drug Class
Table 24. UK Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) – Distribution Channel
Table 25. UK Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) – Hospital Pharmacies
Table 26. UK Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) – Compounding Pharmacies
Table 27. UK Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) – Retail Pharmacies
Table 28. UK Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) – Online Pharmacies
Table 29. France Biosimilars Market Revenue And Forecast to 2030 (US$ Mn) – Disease Indication
Table 30. France Biosimilars Market Revenue And Forecast to 2030 (US$ Mn) – Autoimmune Diseases
Table 31. France Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) – Route of Administration
Table 32. France Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) – Drug Class
Table 33. France Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) – Distribution Channel
Table 34. France Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) – Hospital Pharmacies
Table 35. France Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) – Compounding Pharmacies
Table 36. France Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) – Retail Pharmacies
Table 37. France Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) – Online Pharmacies
Table 38. Italy Biosimilars Market Revenue And Forecast to 2030 (US$ Mn) – Disease Indication
Table 39. Italy Biosimilars Market Revenue And Forecast to 2030 (US$ Mn) – Autoimmune Diseases
Table 40. Italy Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) – Route of Administration
Table 41. Italy Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) – Drug Class
Table 42. Italy Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) – Distribution Channel
Table 43. Italy Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) – Hospital Pharmacies
Table 44. Italy Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) – Compounding Pharmacies
Table 45. Italy Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) – Retail Pharmacies
Table 46. Italy Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) – Online Pharmacies
Table 47. Spain Biosimilars Market Revenue And Forecast to 2030 (US$ Mn) – Disease Indication
Table 48. Spain Biosimilars Market Revenue And Forecast to 2030 (US$ Mn) – Autoimmune Diseases
Table 49. Spain Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) – Route of Administration
Table 50. Spain Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) – Drug Class
Table 51. Spain Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) – Distribution Channel
Table 52. Spain Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) – Hospital Pharmacies
Table 53. Spain Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) – Compounding Pharmacies
Table 54. Spain Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) – Retail Pharmacies
Table 55. Spain Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) – Online Pharmacies
Table 56. Rest of Europe Biosimilars Market Revenue And Forecast to 2030 (US$ Mn) – Disease Indication
Table 57. Rest of Europe Biosimilars Market Revenue And Forecast to 2030 (US$ Mn) – Autoimmune Diseases
Table 58. Rest of Europe Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) – Route of Administration
Table 59. Rest of Europe Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) – Drug Class
Table 60. Rest of Europe Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) – Distribution Channel
Table 61. Rest of Europe Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) – Hospital Pharmacies
Table 62. Rest of Europe Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) – Compounding Pharmacies
Table 63. Rest of Europe Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) – Retail Pharmacies
Table 64. Rest of Europe Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) – Online Pharmacies
Table 65. Recent Inorganic Growth Strategies in the Biosimilars Market
Table 66. Recent Organic Growth Strategies in Biosimilars Market
Table 67. Glossary of Terms
Table 1. Comparison Between Different Drug Developments
Table 2. Europe Biosimilars Market Revenue And Forecast to 2030 (US$ Mn) – Disease Indication
Table 3. Europe Biosimilars Market Revenue And Forecast to 2030 (US$ Mn) – Autoimmune Diseases
Table 4. Europe Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) – Route of Administration
Table 5. Europe Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) – Drug Class
Table 6. Europe Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) – Distribution Channel
Table 7. Europe Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) – Hospital Pharmacies
Table 8. Europe Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) – Compounding Pharmacies
Table 9. Europe Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) – Retail Pharmacies
Table 10. Europe Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) – Online Pharmacies
Table 11. Germany Biosimilars Market Revenue And Forecast to 2030 (US$ Mn) – Disease Indication
Table 12. Germany Biosimilars Market Revenue And Forecast to 2030 (US$ Mn) – Autoimmune Diseases
Table 13. Germany Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) – Route of Administration
Table 14. Germany Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) – Drug Class
Table 15. Germany Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) – Distribution Channel
Table 16. Germany Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) – Hospital Pharmacies
Table 17. Germany Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) – Compounding Pharmacies
Table 18. Germany Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) – Retail Pharmacies
Table 19. Germany Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) – Online Pharmacies
Table 20. UK Biosimilars Market Revenue And Forecast to 2030 (US$ Mn) – Disease Indication
Table 21. UK Biosimilars Market Revenue And Forecast to 2030 (US$ Mn) – Autoimmune Diseases
Table 22. UK Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) – Route of Administration
Table 23. UK Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) – Drug Class
Table 24. UK Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) – Distribution Channel
Table 25. UK Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) – Hospital Pharmacies
Table 26. UK Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) – Compounding Pharmacies
Table 27. UK Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) – Retail Pharmacies
Table 28. UK Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) – Online Pharmacies
Table 29. France Biosimilars Market Revenue And Forecast to 2030 (US$ Mn) – Disease Indication
Table 30. France Biosimilars Market Revenue And Forecast to 2030 (US$ Mn) – Autoimmune Diseases
Table 31. France Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) – Route of Administration
Table 32. France Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) – Drug Class
Table 33. France Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) – Distribution Channel
Table 34. France Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) – Hospital Pharmacies
Table 35. France Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) – Compounding Pharmacies
Table 36. France Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) – Retail Pharmacies
Table 37. France Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) – Online Pharmacies
Table 38. Italy Biosimilars Market Revenue And Forecast to 2030 (US$ Mn) – Disease Indication
Table 39. Italy Biosimilars Market Revenue And Forecast to 2030 (US$ Mn) – Autoimmune Diseases
Table 40. Italy Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) – Route of Administration
Table 41. Italy Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) – Drug Class
Table 42. Italy Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) – Distribution Channel
Table 43. Italy Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) – Hospital Pharmacies
Table 44. Italy Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) – Compounding Pharmacies
Table 45. Italy Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) – Retail Pharmacies
Table 46. Italy Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) – Online Pharmacies
Table 47. Spain Biosimilars Market Revenue And Forecast to 2030 (US$ Mn) – Disease Indication
Table 48. Spain Biosimilars Market Revenue And Forecast to 2030 (US$ Mn) – Autoimmune Diseases
Table 49. Spain Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) – Route of Administration
Table 50. Spain Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) – Drug Class
Table 51. Spain Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) – Distribution Channel
Table 52. Spain Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) – Hospital Pharmacies
Table 53. Spain Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) – Compounding Pharmacies
Table 54. Spain Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) – Retail Pharmacies
Table 55. Spain Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) – Online Pharmacies
Table 56. Rest of Europe Biosimilars Market Revenue And Forecast to 2030 (US$ Mn) – Disease Indication
Table 57. Rest of Europe Biosimilars Market Revenue And Forecast to 2030 (US$ Mn) – Autoimmune Diseases
Table 58. Rest of Europe Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) – Route of Administration
Table 59. Rest of Europe Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) – Drug Class
Table 60. Rest of Europe Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) – Distribution Channel
Table 61. Rest of Europe Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) – Hospital Pharmacies
Table 62. Rest of Europe Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) – Compounding Pharmacies
Table 63. Rest of Europe Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) – Retail Pharmacies
Table 64. Rest of Europe Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) – Online Pharmacies
Table 65. Recent Inorganic Growth Strategies in the Biosimilars Market
Table 66. Recent Organic Growth Strategies in Biosimilars Market
Table 67. Glossary of Terms
LIST OF FIGURES
Figure 1. Biosimilars Market Segmentation
Figure 2. Biosimilars Market, by Region
Figure 3. Key Insights
Figure 4. Europe: PEST Analysis
Figure 5. Europe Biosimilars Market- Key Industry Dynamics
Figure 6. Europe Biosimilars Market: Impact Analysis of Drivers and Restraints
Figure 7. Europe Biosimilars Market – Revenue Forecast and Analysis – 2020–2030
Figure 8. Europe Biosimilars Market Revenue Share, by Type 2022 & 2030 (%)
Figure 9. Cancer: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
Figure 10. Diabetes: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
Figure 11. Autoimmune Diseases: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
Figure 12. Psoriasis: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
Figure 13. Arthritis: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
Figure 14. Others: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
Figure 15. Other Disease Indication: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
Figure 16. Europe Biosimilars Market, by Route of Administration 2022 & 2030 (%)
Figure 17. Intravenous: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
Figure 18. Subcutaneous: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
Figure 19. Others: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
Figure 20. Europe Biosimilars Market Revenue Share, by Drug Class 2022 & 2030 (%)
Figure 21. Granulocyte Colony-Stimulating Factor: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
Figure 22. Insulin: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
Figure 23. TNF Blockers and Monoclonal Antibodies: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
Figure 24. Others: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
Figure 25. Europe Biosimilars Market Revenue Share, by Distribution Channel 2022 & 2030 (%)
Figure 26. Hospital Pharmacies: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
Figure 27. Endocrinologists: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
Figure 28. Immunologists: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
Figure 29. Rheumatologists: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
Figure 30. Oncologists: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
Figure 31. Dermatologists: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
Figure 32. Retina Specialists: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
Figure 33. Others: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
Figure 34. Compounding Pharmacies: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
Figure 35. Endocrinologists: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
Figure 36. Immunologists: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
Figure 37. Rheumatologists: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
Figure 38. Oncologists: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
Figure 39. Dermatologists: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
Figure 40. Retina Specialists: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
Figure 41. Others: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
Figure 42. Retail Pharmacies: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
Figure 43. Endocrinologists: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
Figure 44. Immunologists: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
Figure 45. Rheumatologists: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
Figure 46. Oncologists: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
Figure 47. Dermatologists: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
Figure 48. Retina Specialists: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
Figure 49. Others: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
Figure 50. Online Pharmacies: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
Figure 51. Endocrinologists: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
Figure 52. Immunologists: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
Figure 53. Rheumatologists: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
Figure 54. Oncologists: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
Figure 55. Dermatologists: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
Figure 56. Retina Compounding: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
Figure 57. Others: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
Figure 58. Europe Biosimilars Market, By Region, 2022 ($Mn)
Figure 59. Europe Biosimilars Market Revenue And Forecast to 2030 (US$ Mn)
Figure 60. Europe Biosimilars Market, By Key Countries, 2022 And 2030 (%)
Figure 61. Germany Biosimilars Market Revenue And Forecast to 2030 (US$ Mn)
Figure 62. UK Biosimilars Market Revenue And Forecast to 2030 (US$ Mn)
Figure 63. France Biosimilars Market Revenue And Forecast to 2030 (US$ Mn)
Figure 64. Italy Biosimilars Market Revenue And Forecast to 2030 (US$ Mn)
Figure 65. Spain Biosimilars Market Revenue And Forecast to 2030 (US$ Mn)
Figure 66. Rest of Europe Biosimilars Market Revenue And Forecast to 2030 (US$ Mn)
Figure 67. Pre and Post COVID-19 Impact on Europe Biosimilars Market
Figure 68. Growth Strategies in Biosimilars Market
Figure 1. Biosimilars Market Segmentation
Figure 2. Biosimilars Market, by Region
Figure 3. Key Insights
Figure 4. Europe: PEST Analysis
Figure 5. Europe Biosimilars Market- Key Industry Dynamics
Figure 6. Europe Biosimilars Market: Impact Analysis of Drivers and Restraints
Figure 7. Europe Biosimilars Market – Revenue Forecast and Analysis – 2020–2030
Figure 8. Europe Biosimilars Market Revenue Share, by Type 2022 & 2030 (%)
Figure 9. Cancer: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
Figure 10. Diabetes: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
Figure 11. Autoimmune Diseases: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
Figure 12. Psoriasis: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
Figure 13. Arthritis: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
Figure 14. Others: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
Figure 15. Other Disease Indication: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
Figure 16. Europe Biosimilars Market, by Route of Administration 2022 & 2030 (%)
Figure 17. Intravenous: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
Figure 18. Subcutaneous: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
Figure 19. Others: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
Figure 20. Europe Biosimilars Market Revenue Share, by Drug Class 2022 & 2030 (%)
Figure 21. Granulocyte Colony-Stimulating Factor: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
Figure 22. Insulin: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
Figure 23. TNF Blockers and Monoclonal Antibodies: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
Figure 24. Others: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
Figure 25. Europe Biosimilars Market Revenue Share, by Distribution Channel 2022 & 2030 (%)
Figure 26. Hospital Pharmacies: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
Figure 27. Endocrinologists: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
Figure 28. Immunologists: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
Figure 29. Rheumatologists: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
Figure 30. Oncologists: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
Figure 31. Dermatologists: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
Figure 32. Retina Specialists: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
Figure 33. Others: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
Figure 34. Compounding Pharmacies: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
Figure 35. Endocrinologists: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
Figure 36. Immunologists: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
Figure 37. Rheumatologists: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
Figure 38. Oncologists: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
Figure 39. Dermatologists: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
Figure 40. Retina Specialists: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
Figure 41. Others: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
Figure 42. Retail Pharmacies: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
Figure 43. Endocrinologists: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
Figure 44. Immunologists: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
Figure 45. Rheumatologists: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
Figure 46. Oncologists: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
Figure 47. Dermatologists: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
Figure 48. Retina Specialists: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
Figure 49. Others: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
Figure 50. Online Pharmacies: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
Figure 51. Endocrinologists: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
Figure 52. Immunologists: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
Figure 53. Rheumatologists: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
Figure 54. Oncologists: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
Figure 55. Dermatologists: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
Figure 56. Retina Compounding: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
Figure 57. Others: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
Figure 58. Europe Biosimilars Market, By Region, 2022 ($Mn)
Figure 59. Europe Biosimilars Market Revenue And Forecast to 2030 (US$ Mn)
Figure 60. Europe Biosimilars Market, By Key Countries, 2022 And 2030 (%)
Figure 61. Germany Biosimilars Market Revenue And Forecast to 2030 (US$ Mn)
Figure 62. UK Biosimilars Market Revenue And Forecast to 2030 (US$ Mn)
Figure 63. France Biosimilars Market Revenue And Forecast to 2030 (US$ Mn)
Figure 64. Italy Biosimilars Market Revenue And Forecast to 2030 (US$ Mn)
Figure 65. Spain Biosimilars Market Revenue And Forecast to 2030 (US$ Mn)
Figure 66. Rest of Europe Biosimilars Market Revenue And Forecast to 2030 (US$ Mn)
Figure 67. Pre and Post COVID-19 Impact on Europe Biosimilars Market
Figure 68. Growth Strategies in Biosimilars Market
